MHRA Drug Safety Update: January 2021

  • Home
  • News
  • MHRA Drug Safety Update: January 2021
Add to CPD

MHRA Drug Safety Update: January 2021

The January 2021 Medicines and Healthcare Products Regulatory Agency (MHRA) Drug Safety Update highlights the following:

  • Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
  • Covid-19 vaccines (Pfizer/BioNTech and AstraZeneca): current advice
  • Dimethyl fumarate (Tecfidera): updated advice on the risk of progressive multifocal leukoencephalopathy (PML) associated with mild lymphopenia
  • Fingolimod (Gilenyaâ–¼ ): updated advice about the risks of serious liver injury and herpes meningoencephalitis
  • SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
  • Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations
  • Letters and drug alerts sent to healthcare professionals in December 2020 

Please refer to the update for full details.  For more information, contact the Medicines Management Team.

t: 020 3688 2900

MHRA Drug Safety Update January 2021

Expiry date: Jan 12th, 2022